Compare Stocks: HOWL, LUCD, NGEN, and MDWD

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HOWL Werewolf Therapeutics	$0.98 +1.4%	$0.53	$0.27 ▼ $2.38	$46.96M	0.51	20.22 million shs	663,074 shs
LUCD Lucid Diagnostics	$0.90 -4.5%	$0.98	$0.86 ▼ $1.63	$190.95M	1.1	773,605 shs	961,103 shs
MDWD MediWound	$13.44 +1.1%	$13.94	$12.52 ▼ $20.30	$170.81M	0.14	92,684 shs	195,093 shs
NGEN NervGen Pharma	$2.19 -6.0%	$1.88	$1.58 ▼ $6.30	$187.87M	N/A	590,388 shs	713,735 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HOWL Werewolf Therapeutics	+1.42%	+2.35%	+146.79%	+168.49%	-26.32%
LUCD Lucid Diagnostics	-4.54%	-7.94%	-7.27%	-11.21%	-27.09%
MDWD MediWound	+1.13%	+6.50%	-6.60%	-3.03%	-19.71%
NGEN NervGen Pharma	-6.01%	-5.60%	+28.07%	+26.59%	+218,999,900.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HOWL Werewolf Therapeutics	$0.98 +1.4%	$0.53	$0.27 ▼ $2.38	$46.96M	0.51	20.22 million shs	663,074 shs
LUCD Lucid Diagnostics	$0.90 -4.5%	$0.98	$0.86 ▼ $1.63	$190.95M	1.1	773,605 shs	961,103 shs
MDWD MediWound	$13.44 +1.1%	$13.94	$12.52 ▼ $20.30	$170.81M	0.14	92,684 shs	195,093 shs
NGEN NervGen Pharma	$2.19 -6.0%	$1.88	$1.58 ▼ $6.30	$187.87M	N/A	590,388 shs	713,735 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HOWL Werewolf Therapeutics	+1.42%	+2.35%	+146.79%	+168.49%	-26.32%
LUCD Lucid Diagnostics	-4.54%	-7.94%	-7.27%	-11.21%	-27.09%
MDWD MediWound	+1.13%	+6.50%	-6.60%	-3.03%	-19.71%
NGEN NervGen Pharma	-6.01%	-5.60%	+28.07%	+26.59%	+218,999,900.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HOWL Werewolf Therapeutics	2.14	Hold	$4.00	308.16% Upside
LUCD Lucid Diagnostics	2.60	Moderate Buy	$4.19	366.94% Upside
MDWD MediWound	2.25	Hold	$33.00	145.54% Upside
NGEN NervGen Pharma	2.83	Moderate Buy	$14.00	539.27% Upside

Current Analyst Ratings Breakdown

Latest HOWL, LUCD, NGEN, and MDWD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2026	LUCD Lucid Diagnostics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/17/2026	LUCD Lucid Diagnostics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$2.50
8/14/2026	MDWD MediWound	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$32.00 ➝ $30.00
8/4/2026	LUCD Lucid Diagnostics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/4/2026	NGEN NervGen Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/21/2026	NGEN NervGen Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/20/2026	LUCD Lucid Diagnostics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/17/2026	MDWD MediWound	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/13/2026	NGEN NervGen Pharma	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$10.00
6/16/2026	HOWL Werewolf Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/11/2026	NGEN NervGen Pharma	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy

(Data available from 9/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HOWL Werewolf Therapeutics	$21M	2.27	N/A	N/A	$0.51 per share	1.92
LUCD Lucid Diagnostics	$4.71M	38.70	N/A	N/A	($0.31) per share	-2.89
MDWD MediWound	$16.96M	10.18	N/A	N/A	$3.40 per share	3.95
NGEN NervGen Pharma	N/A	N/A	N/A	N/A	$0.03 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HOWL Werewolf Therapeutics	-$60.82M	-$0.76	N/A	N/A	N/A	N/A	-166.99%	-59.88%	11/3/2026 (Estimated)
LUCD Lucid Diagnostics	-$58.01M	-$0.47	N/A	N/A	N/A	-959.76%	N/A	-119.57%	11/11/2026 (Estimated)
MDWD MediWound	-$23.88M	-$1.80	N/A	N/A	N/A	-170.10%	-47.24%	-24.27%	11/19/2026 (Estimated)
NGEN NervGen Pharma	-$31.58M	-$0.46	N/A	N/A	N/A	N/A	-1,259.82%	-199.79%	N/A

Latest HOWL, LUCD, NGEN, and MDWD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	LUCD Lucid Diagnostics	-$0.0567	-$0.06	-$0.0033	-$0.08	$1.43 million	$1.47 million
8/13/2026	Q2 2026	MDWD MediWound	-$0.7617	-$0.77	-$0.0083	-$0.77	$2.59 million	$3.09 million
8/13/2026	Q2 2026	NGEN NervGen Pharma	-$0.09	-$0.37	-$0.28	-$0.37	N/A	N/A
7/31/2026	Q2 2026	HOWL Werewolf Therapeutics	-$0.28	$0.08	+$0.36	$0.08	$21.00 million	$21.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
HOWL Werewolf Therapeutics	N/A	N/A	N/A	N/A	N/A
LUCD Lucid Diagnostics	N/A	N/A	N/A	N/A	N/A
MDWD MediWound	N/A	N/A	N/A	N/A	N/A
NGEN NervGen Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HOWL Werewolf Therapeutics	N/A	2.91	2.91
LUCD Lucid Diagnostics	N/A	1.33	1.31
MDWD MediWound	N/A	2.32	2.09
NGEN NervGen Pharma	N/A	1.23	1.23

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HOWL Werewolf Therapeutics	64.84%
LUCD Lucid Diagnostics	74.01%
MDWD MediWound	46.83%
NGEN NervGen Pharma	N/A

Insider Ownership

Company	Insider Ownership
HOWL Werewolf Therapeutics	23.60%
LUCD Lucid Diagnostics	6.90%
MDWD MediWound	9.20%
NGEN NervGen Pharma	5.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HOWL Werewolf Therapeutics	40	48.60 million	37.13 million	Optionable
LUCD Lucid Diagnostics	70	203.24 million	189.22 million	No Data
MDWD MediWound	80	12.85 million	11.67 million	Optionable
NGEN NervGen Pharma	N/A	80.63 million	N/A	N/A

HOWL, LUCD, NGEN, and MDWD Headlines

Recent News About These Companies

Brokerages Set NervGen Pharma (NASDAQ:NGEN) PT at $14.00

August 30, 2026 | americanbankingnews.com

NervGen Pharma (NASDAQ:NGEN) Given Average Recommendation of "Moderate Buy" by Analysts

August 25, 2026 | marketbeat.com

Empery Asset Management LP Invests $8.24 Billion in NervGen Pharma $NGEN

August 22, 2026 | marketbeat.com

NervGen Pharma (NASDAQ:NGEN) Stock Rating Lowered by Wall Street Zen

August 15, 2026 | marketbeat.com

NervGen Pharma Corp.: NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates

August 13, 2026 | finanznachrichten.de

NervGen Pharma Posts Larger Q2 2026 Loss but Strengthens Cash Position

August 13, 2026 | tipranks.com

NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates

August 13, 2026 | globenewswire.com

NervGen Pharma (NGEN) Gains Ground: Biotech Stock Holds Above Key Support - Iron Condor Alert

July 14, 2026 | donanimhaber.comD

NervGen Pharma Corp. : NGEN

July 13, 2026 | 247wallst.com

NervGen Pharma Sets Up US$50 Million ATM Equity Program With Leerink Partners

July 2, 2026 | tipranks.com

NervGen Pharma: I Think The Biggest Risks Are Now Behind It

July 2, 2026 | seekingalpha.com

NervGen rises as TD Cowen issues new Buy on lead asset

June 11, 2026 | seekingalpha.com

NGEN Share News Today

June 10, 2026 | uk.investing.com

NervGen Pharma Raises US$60 Million in Underwritten Offering to Fund NVG-291 Program

June 1, 2026 | tipranks.com

NervGen Reports Objective Neural Recovery Signal for NVG-291 in Chronic SCI Ahead of Phase 3

May 26, 2026 | tipranks.com

Why Is NervGen Pharma Stock Gaining Tuesday?

May 26, 2026 | benzinga.com

NervGen Pharma Reports Positive Biomechanical Gait Analysis Results for NVG-291 Demonstrating Genuine Neural Recovery in Chronic Tetraplegia

May 26, 2026 | quiverquant.comQ

NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study

May 26, 2026 | globenewswire.com

NervGen Pharma Rings the Nasdaq Stock Market Closing Bell

May 25, 2026 | nasdaq.com

NervGen Pharma (NGEN) Receives a Buy from Stifel Nicolaus

May 25, 2026 | theglobeandmail.com

NervGen Pharma stock tumbles on dilutive share offering

May 22, 2026 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

HOWL, LUCD, NGEN, and MDWD Company Descriptions

Werewolf Therapeutics NASDAQ:HOWL

$0.98 +0.01 (+1.42%)

Closing price 09/8/2026 04:00 PM Eastern

Extended Trading

$0.96 -0.02 (-1.53%)

As of 09/8/2026 07:59 PM Eastern

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

Lucid Diagnostics NASDAQ:LUCD

$0.90 -0.04 (-4.54%)

Closing price 09/8/2026 04:00 PM Eastern

Extended Trading

$0.92 +0.02 (+2.03%)

As of 09/8/2026 07:55 PM Eastern

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

MediWound NASDAQ:MDWD

$13.44 +0.15 (+1.13%)

Closing price 09/8/2026 04:00 PM Eastern

Extended Trading

$13.40 -0.04 (-0.26%)

As of 09/8/2026 07:30 PM Eastern

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

NervGen Pharma NASDAQ:NGEN

$2.19 -0.14 (-6.01%)

Closing price 09/8/2026 04:00 PM Eastern

Extended Trading

$2.22 +0.02 (+1.14%)

As of 09/8/2026 07:46 PM Eastern

NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HOWL, LUCD, NGEN, and MDWD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HOWL, LUCD, NGEN, and MDWD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HOWL, LUCD, NGEN, and MDWD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

HOWL, LUCD, NGEN, and MDWD Company Descriptions

Werewolf Therapeutics NASDAQ:HOWL

Lucid Diagnostics NASDAQ:LUCD

MediWound NASDAQ:MDWD

NervGen Pharma NASDAQ:NGEN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HOWL, LUCD, NGEN, and MDWD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HOWL, LUCD, NGEN, and MDWD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HOWL, LUCD, NGEN, and MDWD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

HOWL, LUCD, NGEN, and MDWD Company Descriptions

Werewolf Therapeutics NASDAQ:HOWL

Lucid Diagnostics NASDAQ:LUCD

MediWound NASDAQ:MDWD

NervGen Pharma NASDAQ:NGEN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools